Latest Articles
The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer - Targeted Oncology
The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer Targeted Oncology
Published: Dec. 8, 2024, 5 p.m.
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - Oncology News Central
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” Oncology News Central
Published: Dec. 5, 2024, 12:54 p.m.
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - oncologynewscentral.com
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” oncologynewscentral.com
Published: Dec. 5, 2024, 12:54 p.m.
Recommendations and Future Directions of Genetic Testing for CLL - Targeted Oncology
Recommendations and Future Directions of Genetic Testing for CLL Targeted Oncology
Published: Dec. 3, 2024, 1 a.m.
3 FDA Approvals Signal Year of Change for Endometrial Cancer Care - Oncology News Central
3 FDA Approvals Signal Year of Change for Endometrial Cancer Care Oncology News Central
Published: Nov. 13, 2024, 11:41 a.m.
3 FDA Approvals Signal Year of Change for Endometrial Cancer Care - oncologynewscentral.com
3 FDA Approvals Signal Year of Change for Endometrial Cancer Care oncologynewscentral.com
Published: Nov. 13, 2024, 11:41 a.m.
Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium - The Manila Times
Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium The Manila Times
Published: Oct. 23, 2024, 10:06 a.m.
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central
Published: June 17, 2024, 7 a.m.
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PR Newswire
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire
Published: April 24, 2024, 7 a.m.
Link copied to clipboard!